Rectal indomethacin versus placebo to reduce the incidence of pancreatitis after endoscopic retrograde cholangiopancreatography: results of a controlled clinical trial

Víctor Fernando Andrade-Dávila, Mariana Chávez-Tostado, Carlos Dávalos-Cobián, Jesús García-Correa, Alejandro Montaño-Loza, Clotilde Fuentes-Orozco, Michel Dassaejv Macías-Amezcua, Jesús García-Rentería, Jorge Rendón-Félix, José Antonio Cortés-Lares, Gabriela Ambriz-González, Ana Olivia Cortés-Flores, Andrea del Socorro Alvarez-Villaseñor, Alejandro González-Ojeda, Víctor Fernando Andrade-Dávila, Mariana Chávez-Tostado, Carlos Dávalos-Cobián, Jesús García-Correa, Alejandro Montaño-Loza, Clotilde Fuentes-Orozco, Michel Dassaejv Macías-Amezcua, Jesús García-Rentería, Jorge Rendón-Félix, José Antonio Cortés-Lares, Gabriela Ambriz-González, Ana Olivia Cortés-Flores, Andrea del Socorro Alvarez-Villaseñor, Alejandro González-Ojeda

Abstract

Background: Acute pancreatitis is the most common major complication after endoscopic retrograde cholangiopancreatography (ERCP). Many drugs have been evaluated for prophylaxis, including nonsteroidal anti-inflammatory drugs (NSAIDs), which are potent inhibitors of phospholipase A2 and play a role in the pathogenesis of acute pancreatitis. Rectal NSAIDs have been shown in prospective studies to decrease the incidence of this complication, but the indication is not generalized in clinical practice. The aim of this study was to evaluate the efficacy of rectal administration of indomethacin in reducing the incidence of post-ERCP pancreatitis in high-risk patients.

Methods: This was a controlled clinical trial where patients with an elevated risk of developing post-ERCP pancreatitis were assigned to receive 100 mg of rectal indomethacin or a 2.6 g suppository of glycerin immediately after ERCP, without placement of a pancreatic stent. The patients were determined to be at high risk based on validated patient- and procedure-related risk factors. Post-ERCP pancreatitis was defined as the presence of new upper abdominal pain, hyperamylasemia/hyperlipasemia (at least three times the upper limit) 2 hours after the procedure and hospitalization at least 48 hours because of the complication. Pancreatitis severity was defined according to Cotton's criteria.

Results: One hundred sixty-six patients were included; 82 in the study group and 84 in the placebo group. Patients had at least one major and/or two minor risk factors for developing post-ERCP pancreatitis. The incidence of the complication was 4.87% (4/82) in the study group and 20.23% (17/84) in the placebo group; this difference was significant (P = 0.01). According to Cotton's criteria, 17 patients (80.9%) developed mild pancreatitis and 4 (19.1%) had moderate pancreatitis; 3 of these 4 patients belonged to the placebo group (P = 0.60). Based on these results, an absolute risk reduction of 0.15 (15%), a relative risk reduction of 0.75 (75%) and a number needed to treat of 6.5 patients were calculated to prevent an episode of post-ERCP pancreatitis. There was no mortality.

Conclusions: Rectal indomethacin reduced the incidence of post-ERCP pancreatitis among patients at high risk of developing this complication.

Trial registration: National Clinical Trials NCT02110810. Date April 7, 2014.

Figures

Fig. 1
Fig. 1
Distribution of patients included in the study
Fig. 2
Fig. 2
Incidence and distribution of mild and moderate PEP between groups

References

    1. Freeman ML. Complications of endoscopic retrograde cholangiopancreatography: avoidance and management. Gastrointes Endosc Clin N Am. 2012;22:567–586. doi: 10.1016/j.giec.2012.05.001.
    1. Balmadrid B, Kozarek R. Prevention and management of adverse events of endoscopic retrograde cholangiopancreatopgraphy. Gastrointest Esdosc Clin N Am. 2013;23:385–403. doi: 10.1016/j.giec.2012.12.007.
    1. Freeman ML, Nelson DB, Sherman S, Haber GB, Herman ME, Dorsher PJ, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med. 1996;335:909–18.
    1. Masci E, Mariani A, Curioni S, Testoni PA. Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis. Endoscopy. 2003;35:830–4. doi: 10.1055/s-2003-42614.
    1. Dumonceau JM, Andriulli A, Deviere J, Mariani A, Rigaux J, Baron TH, et al. European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis. Endoscopy. 2010;42:503–15.
    1. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology. American College of Gastroenterology guideline: Management of acute pancreatitis. Am J Gastroenterol. 2013;108:1400–16. doi: 10.1038/ajg.2013.218.
    1. Mazaki T, Mado K, Masuda H, Shiono M. Prophylactic pancreatic stent placement and post-ERCP pancreatitis: An updated meta-analysis. J Gastroenterol. 2013;49:343–355. doi: 10.1007/s00535-013-0806-1.
    1. Testoni PA. Therapy: Can rectal NSAIDs prevent post-ERCP pancreatitis? Nat Rev Gastroenterol Hepatol. 2012;9:429–430. doi: 10.1038/nrgastro.2012.117.
    1. Cheon YK. Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach? Korean J Intern Med. 2013;28:141–148. doi: 10.3904/kjim.2013.28.2.141.
    1. Dumonceau JM, Rigaux J, Kahaleh M, Gomez CM, Vandermeeren A, Devière J. Prophylaxis of post-ERCP pancreatitis: a practice survey. Gastrointest Endosc. 2010;71:934–9. doi: 10.1016/j.gie.2009.10.055.
    1. Hanna MS, Portal AJ, Dhanda AD, Przemioslo R. UK wide survey on the prevention of post-ERCP pancreatitis. Frontline Gastroenterol. 2014;5:103110. doi: 10.1136/flgastro-2013-100323.
    1. Elmunzer BJ, Waljee AK, Elta GH, Taylor JR, Fehmi SM, Higgins PD. A meta-analysis of rectal NSAIDs in the prevention of post-ERCP pancreatitis. Gut. 2008;57:1262–1267. doi: 10.1136/gut.2007.140756.
    1. Dai HF, Wang XW, Zhao K. Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis: A meta-analysis. Hepatobilliary Pancreat Dis Int. 2009;8:11–16.
    1. Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003;124:1786–1791. doi: 10.1016/S0016-5085(03)00384-6.
    1. Sotoudenhmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007;102:978–83.
    1. Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, et al. U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012;366:1414–22.
    1. Rustagi T, Jamidar PA. Endoscopic Retrograde Cholangiopancreatography-Related Adverse Events: General Overview. Gastrointest Endosc Clin N Am. 2015;97:97–110. doi: 10.1016/j.giec.2014.09.005.
    1. Rustagi T, Jamidar PA. Endoscopic Retrograde Cholangiopancreatography (ERCP)-Related Adverse Events: Post-ERCP Pancreatitis. Gastrointest Endosc Clin N Am. 2015;97:107–121. doi: 10.1016/j.giec.2014.09.006.
    1. Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991;37:383–93.
    1. Kawai K, Akasaka Y, Murakami K, Tada M, Koli Y. Endoscopic sphincterotomy of the ampulla of Vater. Gastrointest Endosc. 1974;20:148–151. doi: 10.1016/S0016-5107(74)73914-1.
    1. Cooper ST, Slivka A. Incidence, risk factors, and prevention of post-ERCP pancreatitis. Gastroenterol Clin North Am. 2007;36:259–276. doi: 10.1016/j.gtc.2007.03.006.
    1. Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008;23:e11–e16. doi: 10.1111/j.1440-1746.2007.05096.x.
    1. Montaño Loza A, Rodríguez Lomelí X, García Correa JE, Dávalos Cobián C, Cervantes Guevara G, Medrano Muñoz F, et al. Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes. Rev Esp Enferm Dig. 2007;99:330–6.
    1. Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial. Gastrointest Endosc. 2007;66:1126–32.
    1. Senol A, Saritas U, Demirkan H. Efficacy of intramuscular diclofenac and fluid replacement in prevention of post-ERCP pancreatitis. World J Gastroenterol. 2009;15:3999–4004. doi: 10.3748/wjg.15.3999.
    1. Otsuka T, Kawazoe S, Nakashita S, Kamachi S, Oeda S, Sumida C, et al. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012;47:912–7.
    1. Döbrönte Z, Toldy E, Márk L, Sarang K, Lakner L. Effects of rectal indomethacin in the prevention of post-ERCP acute pancreatitis. Orv Hetil. 2012;153:990–996. doi: 10.1556/OH.2012.29403.
    1. Abu-Safieh Y, Altiti R, Lobadeh M. Diclofenac vs. Placebo in a randomized double blind controlled trial, in post ERCP pancreatitis. Am J Clin Med Res. 2014;2:43–46. doi: 10.12691/ajcmr-2-2-1.
    1. Döbrönte Z, Szepes Z, Izbéki F, Gervain J, Lakatos L, Pécsi G, et al. Is rectal indomethacin effective in preventing of post-endoscopic retrograde cholangiopancreatography pancreatitis? World J Gastroenterol. 2014;20:10151–7.
    1. Zheng MH, Xia HH, Chen YP. Rectal administration of NSAIDs in the prevention of post-ERCP pancreatitis: a complementary meta-analysis. Gut. 2008;57:1632–1633.
    1. Ding X, Chen M, Huang S, Zhang S, Zou X. Nonsteroidal anti-inflammatory drugs for prevention of post-ERCP pancreatitis: a meta-analysis. Gastrointest Endosc. 2012;76:1152–1159. doi: 10.1016/j.gie.2012.08.021.
    1. Akbar A, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol. 2013;11:778–783. doi: 10.1016/j.cgh.2012.12.043.
    1. Yaghoobi M, Rolland S, Waschke KA, McNabb-Baltar J, Martel M, Bijarchi R, et al. Meta-analysis: rectal indomethacin for the prevention of post-ERCP pancreatitis. Aliment Pharmacol Ther. 2013;38:995–1001.
    1. Sun HL, Han B, Zhai HP, Cheng XH, Ma K. Rectal NSAIDs for the prevention of post-ERCP pancreatitis: A meta-analysis of randomized controlled trials. Surgeon. 2014;12:141–7. doi: 10.1016/j.surge.2013.10.010.
    1. Sethi S, Sethi N, Wadhwa V, Garud S, Brown A. A meta-analysis on the role of rectal diclofenac and indomethacin in the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Pancreas. 2014;43:190–197. doi: 10.1097/MPA.0000000000000090.
    1. Ahmad D, Lopez KT, Esmadi MA, Oroszi G, Matteson-Kome ML, Choudhary A, et al. The Effect of indomethacin in the prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis. Pancreas. 2014;43:338–42.
    1. Puig I, Calvet X, Baylina M, Isava A, Sort P, Llaó J, et al. How and When Should NSAIDs Be Used for Preventing Post-ERCP Pancreatitis? A Systematic Review and Meta-Analysis. PLoS One. 2014;9, e92922.
    1. Choksi NS, Fogel EL, Cote GA, Romagnuolo J, Elta GH, Scheiman JM, et al. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. Gastronitest Endosc. 2015;81:150–5.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera